163 related articles for article (PubMed ID: 29430546)
21. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis.
Jacob S; Viegas S; Leite MI; Webster R; Cossins J; Kennett R; Hilton-Jones D; Morgan BP; Vincent A
Arch Neurol; 2012 Aug; 69(8):994-1001. PubMed ID: 22689047
[TBL] [Abstract][Full Text] [Related]
22. Oxidative modifications of blood serum proteins in myasthenia gravis.
Adamczyk-Sowa M; Bieszczad-Bedrejczuk E; Galiniak S; Rozmiłowska I; Czyżewski D; Bartosz G; Sadowska-Bartosz I
J Neuroimmunol; 2017 Apr; 305():145-153. PubMed ID: 28284335
[TBL] [Abstract][Full Text] [Related]
23. Ocular manifestation and generalization after ocular onset in ocular myasthenia gravis: A 5-year analysis.
Kemchoknatee P; Arepagorn A; Srisombut T
Asian Pac J Allergy Immunol; 2021 Oct; ():. PubMed ID: 34717528
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Gaze Photographs in Diagnosing Ocular Myasthenia Gravis.
Ahn J; Park KS; Kim JS; Hwang JM
J Clin Neurol; 2018 Jul; 14(3):333-338. PubMed ID: 29856158
[TBL] [Abstract][Full Text] [Related]
25. Thymus involvement in myasthenia gravis: Epidemiological and clinical impacts of different self-tolerance breakdown mechanisms.
Karni A; Asmail A; Drory VE; Kolb H; Kesler A
J Neuroimmunol; 2016 Sep; 298():58-62. PubMed ID: 27609276
[TBL] [Abstract][Full Text] [Related]
26. Single-fiber electromyography in the orbicularis oculi muscle in patients with ocular myasthenia gravis symptoms: does abnormal jitter predict response to treatment?
Rakocevic G; Moster M; Floeter MK
BMC Neurol; 2017 Jun; 17(1):108. PubMed ID: 28592233
[TBL] [Abstract][Full Text] [Related]
27. Clinical features and treatment status of antiacetylcholine receptor antibody-positive ocular myasthenia gravis.
Isshiki Y; Mimura O; Gomi F
Jpn J Ophthalmol; 2020 Nov; 64(6):628-634. PubMed ID: 32936398
[TBL] [Abstract][Full Text] [Related]
28. A new mouse model of autoimmune ocular myasthenia gravis.
Yang H; Wu B; Tüzün E; Saini SS; Li J; Allman W; Higgs S; Xiao TL; Christadoss P
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5101-11. PubMed ID: 17962462
[TBL] [Abstract][Full Text] [Related]
29. [Prognosis of thymectomy in treatment of ocular myasthenia gravis and relevant influencing factors].
Deng Y; Zhang X
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(27):1922-5. PubMed ID: 19953918
[TBL] [Abstract][Full Text] [Related]
30. Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis.
Allen JA; Scala S; Jones HR
Muscle Nerve; 2010 Mar; 41(3):379-84. PubMed ID: 19918767
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Peripheral Blood Regulatory T Cells and Functional Subsets Between Ocular and Generalized Myasthenia Gravis.
Rao J; Li S; Wang X; Cheng Q; Ji Y; Fu W; Huang H; Shi L; Wu X
Front Med (Lausanne); 2022; 9():851808. PubMed ID: 35755064
[TBL] [Abstract][Full Text] [Related]
32. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.
Mittal MK; Barohn RJ; Pasnoor M; McVey A; Herbelin L; Whittaker T; Dimachkie M
J Clin Neuromuscul Dis; 2011 Sep; 13(1):46-52. PubMed ID: 22361625
[TBL] [Abstract][Full Text] [Related]
33. Comparison of peripheral blood B cell subset ratios and B cell-related cytokine levels between ocular and generalized myasthenia gravis.
Hu Y; Wang J; Rao J; Xu X; Cheng Y; Yan L; Wu Y; Wu N; Wu X
Int Immunopharmacol; 2020 Mar; 80():106130. PubMed ID: 31978800
[TBL] [Abstract][Full Text] [Related]
34. The Usefulness of Anti-acetylcholine Receptor Binding Antibody Testing in Diagnosing Ocular Myasthenia Gravis.
Chung IY; Sheth SJ; Wells KK; Campbell TG
J Neuroophthalmol; 2021 Dec; 41(4):e627-e630. PubMed ID: 32868574
[TBL] [Abstract][Full Text] [Related]
35. Ocular Myasthenia Gravis: A Current Overview.
Behbehani R
Eye Brain; 2023; 15():1-13. PubMed ID: 36778719
[TBL] [Abstract][Full Text] [Related]
36. [Ocular myasthenia gravis: diagnostic aspects and evolution].
de Entrambasaguas M; López-Bernabé R; López-Alemany M
Rev Neurol; 2007 Apr 1-15; 44(7):397-403. PubMed ID: 17420965
[TBL] [Abstract][Full Text] [Related]
37. SFEMG in ocular myasthenia gravis diagnosis.
Padua L; Stalberg E; LoMonaco M; Evoli A; Batocchi A; Tonali P
Clin Neurophysiol; 2000 Jul; 111(7):1203-7. PubMed ID: 10880794
[TBL] [Abstract][Full Text] [Related]
38. Lack of Immunotherapy as the Only Predictor of Secondary Generalization in Very-Late-Onset Myasthenia Gravis With Pure Ocular Onset.
Zhao S; Yan X; Ding J; Ren K; Sun S; Lu J; Zhang C; Zhang K; Li Z; Guo J
Front Neurol; 2022; 13():857402. PubMed ID: 35547386
[TBL] [Abstract][Full Text] [Related]
39. Factors affecting outcome in ocular myasthenia gravis.
Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
[TBL] [Abstract][Full Text] [Related]
40. T-cell recognition of muscle acetylcholine receptor subunits in generalized and ocular myasthenia gravis.
Wang ZY; Okita DK; Howard J; Conti-Fine BM
Neurology; 1998 Apr; 50(4):1045-54. PubMed ID: 9566393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
